1. Home
  2. My blogs
  3. Aptamers: the emerging class of future anticoagulation for vascular disease
April 29, 2010

Aptamers: the emerging class of future anticoagulation for vascular disease

Expert Review of Cardiovascular Therapy , 04/29/10

Kuliczkowski W et al. – Representing an attractive new therapeutic class, aptamers are nucleic acid ligand with a high affinity and specificity for proteins involved in the clot growth. Potential antidote control of aptamer activity offers an important advance in anticoagulant safety. Aptamers are a promising class of compounds, both for target validation and therapy. As designer drugs, they exhibit high specificity, high affinity and modifiable bioavailability. The ability to generate inhibitors with such properties against a variety of target proteins will be valuable as the human genome and proteome are deciphered. This article summarizes current knowledge of aptamers developed against coagulation proteins, focusing on the biology, pharmacology, preclinical and early clinical experience with this novel class of anticoagulants.

03 9789 0088

FRANKSTON

Suite11
Peninsula Private Hospital
525 McClelland Drive

MORNINGTON

Consulting Suites
Beleura Private Hospital
925 Nepean Highway

ROSEBUD

Suite 8
Peninsula Medical Suites
1533 Pt Nepean Road

03 9789 0088

FRANKSTON

Suite11, Peninsula Private Hospital
525 McClelland Drive

MORNINGTON

Consulting Suites, Beleura Private Hospital
925 Nepean Highway

ROSEBUD

Suite 8, Peninsula Medical Suites
1533 Pt Nepean Road

Copyright © Peninsula Heart Centre 2020 | Website by Grendesign